Botanix Pharmaceuticals Shares Plunge 41% Following Capital Raise Announcement
Shares of Botanix Pharmaceuticals Ltd (ASX: BOT) experienced a significant decline on Tuesday, falling 41% to 6.5 cents. This sharp drop followed the company's announcement of a substantial capital raising initiative.
The company announced a capital raise as the catalyst for the stock's decline, securing commitments for a ~$40 million two-tranche placement.
Strategic Capital Raising Details
Botanix has successfully secured commitments for a ~$40 million two-tranche placement from a mix of existing and new institutional and sophisticated investors. The second tranche of this placement is contingent on obtaining shareholder approval.
In addition to the placement, the company plans to offer existing eligible shareholders a security purchase plan (SPP). This SPP is underwritten up to $5 million (before costs) and allows for potential oversubscriptions, also subject to shareholder approval.
Allocation of Funds
The proceeds from both the placement and the security purchase plan are strategically allocated to bolster the company's operations and growth initiatives.
Key areas for fund allocation include:
- Active pharmaceutical ingredient (API) purchases and manufacturing components.
- Setup of an alternate API supplier, aiming to enhance supply chain resilience.
- Advertising and marketing initiatives to drive product growth.
- Operating expenses and working capital.
- Transaction costs associated with the capital raise.
Botanix believes this funding will strengthen its ability to achieve strategic initiatives, including continued growth of Sofdra, adding new products to its fulfillment platform, and enhancing its value proposition for potential mergers and acquisitions.
Executive Chair Highlights Growth and De-risking
Executive Chair Vince Ippolito commented on the capital raise, noting "strong support for the placement from existing and new institutional shareholders."
He highlighted the company's successful first year and underscored the continued strong demand for Sofdra, observing robust quarter-on-quarter growth since its launch. Ippolito also mentioned the recent expansion of the sales force, with 27 additional sales professionals hired, expanding the team to 50, anticipating a positive impact on Sofdra prescription volumes.
Ippolito further emphasized a key benefit of the capital raising, stating that it is "expected to derisk the company's supply chain," providing greater security for future operations.